TGEN - Targeted Genetics Corporation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TGEN - Targeted Genetics Corporation

TGEN 8.005

-1.3%

2:22 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mike McFarland who wrote (435)	3/17/2005 10:57:50 AM
From: 9wald9	Read Replies (1) of 557

Thursday, March 17, 2005 at 9:00EST "Targeted Genetics Announces Preliminary Results From Its Phase II Trial of tgAAVCF in Cystic Fibrosis" Targeted Genetics Corporation (Nasdaq: TGEN) today reported that its Phase II clinical trial of tgAAVCF in patients with mild to moderate cystic fibrosis (CF) failed to meet its primary endpoint of statistically significant improvement in lung function, 30 days following initial administration of tgAAVCF compared to placebo. Based on these results, the Company has decided not to pursue further development of tgAAVCF. The Company will hold a conference call via webcast at 10:30 a.m. EST today, which can be accessed, along with replay information, at www.targetedgenetics.com ...

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next